NASDAQ:CORT

Corcept Therapeutics - CORT Stock Forecast, Price & News

$25.28

-0.28 (-1.10%)

(As of 11/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $24.84
▼
$25.72
50-Day Range: $24.51
▼
$29.96
52-Week Range: $15.82
▼
$30.14

Volume: 821,556 shs
Average Volume: 755,622 shs
Market Capitalization: $2.72 billion

P/E Ratio: 25.28
Dividend Yield: N/A
Price Target: $32.00

Corcept Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.75 Rating Score
Upside/Downside: 26.6% Upside
$32.00 Price Target
Short Interest: Bearish
18.34% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.03
Upright™ Environmental Score
News Sentiment: 0.42
Based on 5 Articles This Week
Insider Trading: Selling Shares
$2.97 M Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

331st out of 1,043 stocks

Pharmaceutical Preparations Industry

142nd out of 510 stocks

3.4

Analyst's Opinion

Consensus Rating
Corcept Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $32.00, Corcept Therapeutics has a forecasted upside of 26.6% from its current price of $25.28.
Amount of Analyst Coverage
Corcept Therapeutics has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
18.34% of the float of Corcept Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Corcept Therapeutics has a short interest ratio ("days to cover") of 30.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Corcept Therapeutics has recently decreased by 0.81%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Corcept Therapeutics does not currently pay a dividend.
Dividend Growth
Corcept Therapeutics does not have a long track record of dividend growth.

4.5

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Corcept Therapeutics has received a 68.53% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Sex hormones and modulators of the genital system (G03)", "Clinical research services for metabolic diseases", and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for Corcept Therapeutics is -1.03.

1.9

News and Social Media Coverage

News Sentiment
Corcept Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.70 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Corcept Therapeutics this week, compared to 2 articles on an average week.
Search Interest
Only 2 people have searched for CORT on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Corcept Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Corcept Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,969,158.00 in company stock.
Percentage Held by Insiders
18.60% of the stock of Corcept Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
78.46% of the stock of Corcept Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Corcept Therapeutics are expected to remain at $0.92 per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Corcept Therapeutics is 25.28, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 125.08.
Price to Earnings Ratio vs. Sector
The P/E ratio of Corcept Therapeutics is 25.28, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 108.23.
Price to Book Value per Share Ratio
Corcept Therapeutics has a P/B Ratio of 5.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Corcept Therapeutics (NASDAQ:CORT) Stock

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Stock News Headlines

November 25, 2022 | americanbankingnews.com

Gary Charles Robb Sells 4,814 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

November 24, 2022 | benzinga.com

Corcept Therapeutics Chief Business Officer Sold $130K In Company Stock

November 23, 2022 | americanbankingnews.com

Gary Charles Robb Sells 10,000 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) Stock

November 22, 2022 | benzinga.com

Corcept Therapeutics Chief Business Officer Trades Company's Stock

November 21, 2022 | americanbankingnews.com

Corcept Therapeutics (NASDAQ:CORT) Upgraded to Strong-Buy by StockNews.com

November 16, 2022 | finance.yahoo.com

Here's Why Corcept Therapeutics (CORT) is a Strong Growth Stock

November 2, 2022 | msn.com

Corcept Therapeutics's Earnings: A Preview

October 21, 2022 | finance.yahoo.com

These 3 Stocks Are Winning the Bear Market -- Here's How

October 20, 2022 | finance.yahoo.com

Corcept (CORT) Thrives on Korlym, Overdependence a Concern

October 18, 2022 | finance.yahoo.com

Corcept Therapeutics (NASDAQ:CORT) jumps 6.8% this week, though earnings growth is still tracking behind three-year shareholder returns

October 13, 2022 | marketwatch.com

Corcept Therapeutics Initiates DAZALS - A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

October 11, 2022 | finance.yahoo.com

Corcept Therapeutics Initiates DAZALS – A Phase 2 Trial in Amyotrophic Lateral Sclerosis (ALS)

October 10, 2022 | nasdaq.com

Insiders sold US$2.0m worth of Corcept Therapeutics Incorporated (NASDAQ:CORT) stock last year, could be a warning sign to watch out for

September 3, 2022 | nasdaq.com

Corcept Therapeutics' (NASDAQ:CORT) earnings growth rate lags the 26% CAGR delivered to shareholders

September 2, 2022 | finance.yahoo.com

Corcept (CORT) Down 8.3% Since Last Earnings Report: Can It Rebound?

August 25, 2022 | finance.yahoo.com

ASRT or CORT: Which Is the Better Value Stock Right Now?

August 21, 2022 | finance.yahoo.com

Do Corcept Therapeutics' (NASDAQ:CORT) Earnings Warrant Your Attention?

August 4, 2022 | finance.yahoo.com

Corcept Therapeutics (CORT) Q2 2022 Earnings Call Transcript

August 3, 2022 | finance.yahoo.com

Corcept Therapeutics (CORT) Q2 Earnings Lag Estimates

August 1, 2022 | apnews.com

Bragar Eagel & Squire, P.C. Is Investigating Carvana, Corcept, Cassava, and Hannon Armstrong and Encourages Investors to Contact the Firm

July 29, 2022 | nasdaq.com

We Ran A Stock Scan For Earnings Growth And Corcept Therapeutics (NASDAQ:CORT) Passed With Ease

July 27, 2022 | seekingalpha.com

Corcept initiated as a buy at Jefferies on 'underappreciated' Cushing's business

July 18, 2022 | nasdaq.com

Interesting CORT Put And Call Options For September 16th

July 15, 2022 | seekingalpha.com

Corcept Therapeutics - Drug Development

July 11, 2022 | nasdaq.com

CORT Crosses Above Average Analyst Target

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CORT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corcept Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CORT Company Calendar

Last Earnings: 11/03/2021
Today: 11/30/2022
Fiscal Year End: 12/31/2022
Next Earnings (Estimated): 2/21/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NASDAQ:CORT
CUSIP: 21835210
CIK: 1088856
Web: www.corcept.com
Phone: (650) 327-3270
Fax: 650-327-3218
Employees: 238
Year Founded: 1998

Price Target and Rating

Average Stock Price Forecast: $32.00
High Stock Price Forecast: $35.00
Low Stock Price Forecast: $30.00
Forecasted Upside/Downside: +26.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.75
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.00
Trailing P/E Ratio: 25.28
Forward P/E Ratio: 27.48
P/E Growth: N/A
Net Income: $112.51 million
Net Margins: 29.37%
Pretax Margin: 32.35%
Return on Equity: 27.49%
Return on Assets: 24.31%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 8.52
Quick Ratio: 8.41

Sales & Book Value

Annual Sales: $365.98 million
Price / Sales: 7.44
Cash Flow: $1.00 per share
Price / Cash Flow: 25.34
Book Value: $4.40 per share
Price / Book: 5.75

Miscellaneous

Outstanding Shares: 107,650,000
Free Float: 87,627,000
Market Cap: $2.72 billion
Optionable: Optionable
Beta: 0.56

Social Links

Key Executives

Dr. Joseph K. Belanoff M.D. (Age 65)
Co-Founder, Pres, CEO & Director
Comp: $1.69M

Mr. Atabak Mokari (Age 45)
CFO & Treasurer
Comp: $687.98k

Dr. Hazel Hunt Ph.D. (Age 62)
Chief Scientific Officer
Comp: $826.67k

Mr. Sean Maduck (Age 45)
Pres of Corcept Endocrinology
Comp: $828.83k

Mr. Gary Charles Robb (Age 59)
Chief Bus. Officer & Sec.
Comp: $900.08k

Mr. Joseph Douglas Lyon (Age 43)
Chief Accounting Officer

Ms. Amy Flood
Chief HR & Communications Officer

Dr. William Guyer Pharm.D. (Age 54)
Chief Devel. Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CORT Stock - Frequently Asked Questions

Should I buy or sell Corcept Therapeutics stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Corcept Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CORT shares.
View CORT analyst ratings or view top-rated stocks.
What is Corcept Therapeutics' stock price forecast for 2023?: 4 brokers have issued 12-month price objectives for Corcept Therapeutics' shares. Their CORT share price forecasts range from $30.00 to $35.00. On average, they expect the company's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 27.8% from the stock's current price.
View analysts price targets for CORT or view top-rated stocks among Wall Street analysts.
How have CORT shares performed in 2022?: Corcept Therapeutics' stock was trading at $19.80 at the beginning of the year. Since then, CORT stock has increased by 26.4% and is now trading at $25.03.
View the best growth stocks for 2022 here.
When is Corcept Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our CORT earnings forecast.
How were Corcept Therapeutics' earnings last quarter?: Corcept Therapeutics Incorporated (NASDAQ:CORT) announced its earnings results on Wednesday, November, 3rd. The biotechnology company reported $0.24 earnings per share for the quarter, beating the consensus estimate of $0.19 by $0.05. The biotechnology company earned $96.13 million during the quarter, compared to analyst estimates of $97.75 million. Corcept Therapeutics had a net margin of 29.37% and a trailing twelve-month return on equity of 27.49%. During the same quarter last year, the company posted $0.17 EPS.
What guidance has Corcept Therapeutics issued on next quarter's earnings?: Corcept Therapeutics updated its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400.00 million-$410.00 million, compared to the consensus revenue estimate of $416.67 million.

What is Joseph K. Belanoff's approval rating as Corcept Therapeutics' CEO?: 6 employees have rated Corcept Therapeutics Chief Executive Officer Joseph K. Belanoff on Glassdoor.com. Joseph K. Belanoff has an approval rating of 100% among the company's employees. This puts Joseph K. Belanoff in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Corcept Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Corcept Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), CA (CA), Alibaba Group (BABA), BlackRock (BLK), Inovio Pharmaceuticals (INO), Pfizer (PFE) and Activision Blizzard (ATVI).
What is Corcept Therapeutics' stock symbol?: Corcept Therapeutics trades on the NASDAQ under the ticker symbol "CORT."
Who are Corcept Therapeutics' major shareholders?: Corcept Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (15.04%), Vanguard Group Inc. (9.60%), Renaissance Technologies LLC (6.69%), Ingalls & Snyder LLC (6.49%), Federated Hermes Inc. (5.16%) and State Street Corp (3.22%). Insiders that own company stock include Daniel N Swisher Jr, G Leonard Baker Jr, G Leonard Baker, Jr, Gary Charles Robb, Joseph Douglas Lyon, Joseph K Belanoff and Sean Maduck.
View institutional ownership trends.
How do I buy shares of Corcept Therapeutics?: Shares of CORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Corcept Therapeutics' stock price today?: One share of CORT stock can currently be purchased for approximately $25.03.
How much money does Corcept Therapeutics make?: Corcept Therapeutics (NASDAQ:CORT) has a market capitalization of $2.69 billion and generates $365.98 million in revenue each year. The biotechnology company earns $112.51 million in net income (profit) each year or $1.00 on an earnings per share basis.
How many employees does Corcept Therapeutics have?: The company employs 238 workers across the globe.
How can I contact Corcept Therapeutics?: Corcept Therapeutics' mailing address is 149 COMMONWEALTH DRIVE, MENLO PARK CA, 94025. The official website for the company is www.corcept.com. The biotechnology company can be reached via phone at (650) 327-3270, via email at cjames@corcept.com, or via fax at 650-327-3218.

This page (NASDAQ:CORT) was last updated on 11/30/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial